Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology 2016-2025
Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2016 to 2025
The Definitive Resource for Structuring and Benchmarking Shared Commercialization Partnerships
The Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology 2016–2025 report provides the most comprehensive analysis available of co-commercialization strategies across the life sciences industry. Featuring 326 detailed deal records and links to publicly available contracts where filed, this fully revised and updated report gives you an unmatched look inside the terms, structures, and strategies behind the industry's most impactful partnerships.
Whether you're negotiating a new alliance or benchmarking existing agreements, this report gives you the data-driven insights you need to craft smarter, stronger, and more profitable deals.
Free report sample
What You’ll Gain
✔ Access 326 Real-World Deals – Get the details on deal structure, revenue sharing, territory splits, and commercialization responsibilities, with links to online contract documents where available.
✔ Understand Winning Structures – See how biopharma leaders split promotional duties, allocate rights, and manage exclusivity across co-promotion and co-marketing agreements.
✔ Negotiate with Confidence – Leverage detailed financial data, including payment terms, to understand what’s standard—and what’s possible.
✔ Learn from the Leaders – Examine how top players like Pfizer, Novartis and AstraZeneca approach co-commercialization.
✔ Access Real Contracts – Where available, review actual SEC-filed agreements to understand deal mechanics that press releases and databases don’t reveal.
✔ Stay Ahead of Market Trends – Track activity from 2016 to 2025, including trends by year, therapy area, technology type, and company A–Z.
Inside the Report – Chapter Overview
Chapter 1: Introduction
An orientation to the structure, purpose, and use of the report.
Chapter 2: Co-promotion and Co-marketing Trends
Covers key industry trends, growth in activity, and strategic rationale for shared commercialization models.
Chapter 3: Deal Structures and Terms
Explains how companies structure these partnerships—including revenue splits, territories, exclusivity, responsibilities, and duration.
Chapter 4: Top Deals by Value
A curated overview of high-value deals with direct links to online records and available SEC-filed contracts.
Chapter 5: Top 25 Most Active Dealmakers
Profiles of the most prolific companies in co-commercialization, each linked to their deal records and available contract documents.
Chapter 6: Deal Analysis by Company, Therapy & Tech
An in-depth review of all co-promotion and co-marketing deals signed since 2016, categorized by company A–Z, therapeutic area, technology type, and contract availability.
Deal Directory
A complete listing of the 326 included deals, each linked to a detailed record in the Current Agreements database, with direct access to contract documents where available.
What’s Included
-
Industry trends in co-promotion and co-marketing (2016–2025)
-
Overview of deal structures and revenue models
-
Analysis of top deals and dealmakers
-
Directory of all deals by company, therapy area, and technology
-
Access to real contract documents (where publicly available)
-
Numerous tables and figures illustrating activity across the industry
Who Should Use This Report?
✅ Business Development & Licensing Teams – Evaluate deal structures and identify ideal partners.
✅ Commercial Strategy & Operations – Plan smarter co-launches and regional strategies.
✅ Legal & Contracts Teams – Benchmark clauses and strengthen negotiation positions with real contract language.
✅ C-Level Executives & Investors – Assess monetization strategies and partnership dynamics in commercial-stage assets.
Due Diligence Made Easy: What You’ll Learn from Contracts
By reviewing actual deal agreements, you can evaluate key aspects such as:
-
What rights are granted or optioned?
-
How is revenue shared and audited?
-
What exclusivity and territory provisions are included?
-
Who handles commercialization, manufacturing, and supply?
-
What is the term and how is termination managed?
-
How are disputes, confidentiality, and publication handled?
-
Which legal jurisdiction is used?
-
Are sublicensing and subcontracting allowed?
-
Which clauses are standardized, and which vary across partners?
Why This Report Matters
Co-promotion and co-marketing strategies have become vital for maximizing commercial potential, especially in competitive or specialty-driven markets. This report delivers critical intelligence on how industry leaders are structuring these deals—giving you a clear path to negotiate better terms, avoid common pitfalls, and select the right partners.
Get ahead of your next deal. Explore the data. Learn from the contracts. Make better decisions.
✔ Access 326 Real-World Deals – Get the details on deal structure, revenue sharing, territory splits, and commercialization responsibilities, with links to online contract documents where available.
✔ Understand Winning Structures – See how biopharma leaders split promotional duties, allocate rights, and manage exclusivity across co-promotion and co-marketing agreements.
✔ Negotiate with Confidence – Leverage detailed financial data, including payment terms, to understand what’s standard—and what’s possible.
✔ Learn from the Leaders – Examine how top players like Pfizer, Novartis and AstraZeneca approach co-commercialization.
✔ Access Real Contracts – Where available, review actual SEC-filed agreements to understand deal mechanics that press releases and databases don’t reveal.
✔ Stay Ahead of Market Trends – Track activity from 2016 to 2025, including trends by year, therapy area, technology type, and company A–Z.
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in co-promotion and co-marketing dealmaking
2.1. Introduction
2.2. Definition of co-promotion and co-marketing deals
2.3. Trends in co-promotion and co-marketing deals since 2016
2.3.1. Co-promotion and co-marketing dealmaking by year, 2016-2025
2.3.2. Co-promotion and co-marketing dealmaking by phase of development, 2016-2025
2.3.3. Co-promotion and co-marketing dealmaking by industry sector, 2016-2025
2.3.4. Co-promotion and co-marketing dealmaking by therapy area, 2016-2025
2.3.5. Co-promotion and co-marketing dealmaking by technology type, 2016-2025
2.3.6. Co-promotion and co-marketing dealmaking by most active company, 2016-2025
2.4. Reasons for entering into co-promotion and co-marketing partnering deals
2.5. The future of co-promotion and co-marketing deals
Chapter 3 – Overview of co-promotion and co-marketing deal structure
3.1. Introduction
3.2. Co-promotion and co-marketing agreement structure
Chapter 4 – Leading co-promotion and co-marketing deals
4.1. Introduction
4.2. Top co-promotion and co-marketing deals by value
Chapter 5 – Top 25 most active co-promotion and co-marketing dealmakers
5.1. Introduction
5.2. Top 25 most active co-promotion and co-marketing dealmakers
Chapter 6 – Co-promotion and co-marketing deals including contracts directory
6.1. Introduction
6.2. Co-promotion and co-marketing deals with contracts 2016-2025
Deal directory
Deal directory – Co-promotion and co-marketing dealmaking by companies A-Z
Deal directory – Co-promotion and co-marketing dealmaking by therapy area
Deal directory – Co-promotion and co-marketing dealmaking by technology type
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering
TABLE OF FIGURES
Figure 1: Definition of co-promotion and co-marketing
Figure 2: Trends in co-promotion and co-marketing deal announcements, 2016-2025
Figure 3: Co-promotion and co-marketing deals signed at each phase of development, 2016-2025
Figure 4: Co-promotion and co-marketing deals by industry sector, 2016-2025
Figure 5: Co-promotion and co-marketing deals by therapy area, 2016-2025
Figure 6: Co-promotion and co-marketing deals by technology type, 2016-2025
Figure 7: Top 25 most active co-promotion and co-marketing dealmakers, 2016-2025
Figure 8: Top co-promotion and co-marketing deals by value, 2016-2025
Figure 9: Most active co-promotion and co-marketing dealmakers, 2016-2025
Pricing options
- $3,995: single-user (encrypted file - one user/device)
- $5,995: multi-user (encrypted file - up to 5 users/devices)
- $7,995: company (unencrypted file)
Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.
Company license files are not encrypted and can be accessed using a PDF Reader.
A full explanation of license type definitions can be found here.
Our guarantee
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Delivery Deadline
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Biopharma Research Ltd based in York, United Kingdom. We have been trading successfully online since 2012 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
3D Medicines, 4D Molecular Therapeutics, Abbvie, AbCellera Biologics, ACADIA Pharmaceuticals, Acceleron Pharma, Accent Therapeutics, ACEA Biosciences, Acelrx Pharmaceuticals, Acerus, AC Immune, Adaptimmune, Adhera Therapeutics, Advanced Biological Laboratories, AEterna Zentaris, Affibody, Affini-T Therapeutics, Agena Bioscience, Agenus Bio, Agilent Technologies, Ajinomoto, Akeso Biopharma, Akoya Biosciences, Aldeyra Therapeutics, Alector, Alexion Pharmaceuticals, Alfasigma, ALK-Abello, Allegis Pharmaceuticals, Allergan, Almirall, Alnylam Pharmaceuticals, Alyvant, Amgen, Amneal Pharmaceuticals, AMRA, AnGes MG, Apellis Pharmaceuticals, Aratana Therapeutics, Arbor Biotechnologies, Arcellx, Arcturus Therapeutics, Arcus Biosciences, Arcutis Biotherapeutics, argenx, Aries Pharmaceuticals, Arima Genomics, Armune Bioscience, ArQule, Arrowhead Pharmaceuticals, Arvinas, Ascend Therapeutics, Ascentage Pharma, Assembly Biosciences, Astellas Pharma, Astex Pharmaceuticals, AstraZeneca, Aurigene Pharmaceutical Services, Aytu BioPharma, Basilea Pharmaceutica, Bausch & Lomb, Baxalta, Bayer, Beam Therapeutics, BeiGene, Beijing Minhai Biotechnology, Belharra Therapeutics, Belintra, Berlin Chemie, Bio-Rad Laboratories, Bio-Techne, BioAge Labs, Biogen, Biognosys, Biological Industries, BioNano Genomics, BioNTech, Blake Insomnia Therapeutics, Bluebird Bio, Blueprint Medicines, Boehringer Ingelheim, Bolt Biotherapeutics, BridgeBio Pharma, Bristol-Myers Squibb, Burning Rock, Cambrooke Therapeutics, Capitainer, Capsida Biotherapeutics, CC Pharma, Celgene, Cellectricon, Cellenion, Cellev8 Nutrition, Cell Guidance Systems, Cenra Healthcare, Centogene, Century Therapeutics, Cevec Pharmaceuticals, Cingulate, Cipher Pharmaceuticals, Complete Genomics, Concordia Pharmaceuticals, CRISPR Therapeutics, CrossLink Bioscience, CSL, CStone Pharmaceuticals, Cue Biopharma, Cullgen, Cullinan Oncology, Cumberland Pharmaceuticals, CureVac, Curi Bio, Curio Genomics, CytomX Therapeutics, Daiichi Sankyo, Delic, Denali Therapeutics, DePuy, DexCom, Dicerna Pharmaceuticals, Dova Pharmaceuticals, Dovetail Genomics, DualityBio, Eagle Genomics, Eagle Pharmaceuticals, EA Pharma, Eckert & Ziegler, ECMOHO, eFFECTOR Therapeutics, Egalet, Eiger BioPharmaceuticals, Eisai, Elanco, Element Biosciences, Eli Lilly, EMC Pharma, Empatica, Enterome Bioscience, Epizyme, Eton Pharmaceuticals, Evofem Biosciences, Exact Sciences, Eyenovia, Fabric Genomics, Fate Therapeutics, Ferring Pharmaceuticals, Foghorn Therapeutics, Fortelinea Software Systems, Fosun Pharmaceutical, Fusion Pharmaceuticals, G1 Therapeutics, Galapagos, GE Healthcare, Genentech, Genmab, Genoox, Genzyme, Gilead Sciences, Glenmark Pharmaceuticals, Goldfinch Bio, GSK, GT Research, H3 Biomedicine, Halyard Health, Hamilton Company, Hanmi Pharmaceutical, Harbin Pharmaceutical Group, HD Biosciences, Heartseed, Helsinn Healthcare, Helsinn Therapeutics, Heron Therapeutics, High Beauty, Hormosan Pharma GmbH, Hovione, iCAD, Iconic Therapeutics, Idorsia, IGM Biosciences, Illumina, Immatics Biotechnologies, Immunicon, ImmunityBio, ImmunoGen, Immunomedics, Incyte, Indegene Lifesystems, Innara Health, Innate Pharma, Innovent Biologics, Insitro, Inspirion Delivery Sciences, Inspirna, Integrated DNA Technologies, Intellia Therapeutics, Ionis Pharmaceuticals, Ironwood Pharmaceuticals, iTeos Therapeutics, Janssen Biotech, Janssen Pharmaceuticals, Jiangsu Alphamab, Jiangsu Carephar Pharmaceutical, Jiangsu Hengrui Pharmaceuticals, Jumpcode Genomics, Kailos Genetics, Kaleo, Kite Pharma, Konica Minolta, Kowa Pharmaceuticals America, KSQ Therapeutics, Kyorin Pharmaceutical, Kyowa Hakko Kirin, Kyverna Therapeutics, LEO Pharma, LG Life Sciences, Life Genomics AB, Loxo Oncology, Lundbeck, Luqa Pharmaceuticals, Luxcel Biosciences, Lygos, Macrogenics, Manchester BIOGEL, MannKind Biopharmaceuticals, Medicines360, MedImmune, Medovate, MEI Pharma, Menarini, Merck and Co, Merck KGaA, Mersana Therapeutics, Mesoblast, Metagenomi, Metavant, MGI Tech, Microsoft, Midatech Pharma, Miltenyi Biotec, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Moderna, Momenta Pharmaceuticals, Morphic Therapeutic, MorphoSys, MSD, Myovant Sciences, NantKwest, Napo Pharmaceuticals, Ncardia, Neotope, NeraCare, Nestle Health Science, Neurexpert, Neuro3 Therapeutics, Neurocrine Biosciences, Nexel, Next&Bio, Nkarta Therapeutics, NovaBay Pharmaceuticals, Novartis, Novoheart, Novo Nordisk, nRichDX, Numab, Nurix Therapeutics, ODI Pharma, Olympus Medical Systems, OncoCyte, OncoDNA, OncoSec Medical, ONK Therapeutics, Ono Pharmaceutical, OptiNose, Orapharma, Orion, Otonomy, Otsuka, Oxford BioMedica, Pacira Biosciences, Paragon Bioservices, Pearsanta, Pfizer, Phil, Pierian, Pieris Pharmaceuticals, Pillar Biosciences, Piramal, Pivot Pharmaceuticals, Poxel, Precision BioSciences, Prelude Therapeutics, Prevail Therapeutics, Protagonist Therapeutics, Protea Biosciences, Proteos, Proteovant Therapeutics, Prothena, Provention Bio, PSI (Population Services International), Purdue Pharma, Pure Pharmaceuticals, QED Therapeutics, QIAGEN, Quanta, Radius Health, Rainbow Scientific, Rakuten Medical, Recludix Pharma, RedHill Biopharma, RefleXion Medical, Regeneron Pharmaceuticals, Regenxbio, Relay Therapeutics, Repare Therapeutics, Resonant Specific Technologies, Revolution Medicines, Rigel Pharmaceuticals, Roche, Roche Diagnostics, Roivant Sciences, Rubicon Genomics, Sage Therapeutics, Sajo Consulting, Salix Pharmaceuticals, Sanofi, Sanofi-Aventis, Sanofi US Services, Santen Pharmaceutical, Sarepta Therapeutics, Sato Pharmaceutical, Schrodinger, Scorpion Therapeutics, Scribe Therapeutics, Seagen, Seattle Genetics, Seren Pharmaceuticals, Seres Therapeutics, Shimadzu, Shionogi, Silicon Biosystems, Simcere Pharmaceuticals, Sirtex Medical, SK Biopharmaceuticals, Solid Biosciences, Sonoma BioTherapeutics, Sonoma Pharmaceuticals, Sosei, SparingVision, Stealth BioTherapeutics, Stoke Therapeutics, StrideBio, STU, Sumitomo Dainippon Pharma, Summit Therapeutics, Sunovion Pharmaceuticals, Sun Pharmaceutical, Sutro Biopharma, Swift Biosciences, Swixx Biopharma, Syndax Pharmaceuticals, Tagomics, Taiho, Taisho Pharmaceutical, Takeda Pharmaceutical, Tango Therapeutics, Teijin, Telix Pharmaceuticals, Terumo Blood and Cell Technologies, Tetraphase Pharmaceuticals, Teva Pharmaceutical Industries, Theravance, Thermo Fisher Scientific, Tilak Healthcare, Tilray, Titan Pharmaceuticals, Tolmar, TRACON Pharmaceuticals, Trovita Health Science, Tyme Technologies, UCB, Ultragenyx Pharmaceuticals, Uni-Bio Science, Universal Cells, Urovant Sciences, US WorldMeds, Verity Pharmaceuticals, Vertex Pharmaceuticals, Vertice Pharma, Vifor Pharma, Vipergen, Vivos Therapeutics, Voyager Therapeutics, Waters Corporation, WAVE Life Sciences, Windsong Radiology, Xellia Pharmaceuticals, Xencor, ZAI Laboratory, Zealand Pharma, Zerion Pharma, Zymeworks
Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.
The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant
Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.
